Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib versus dacarbazine in previously untreated BRAF-mutant advanced or metastatic melanoma
2009-015298-11Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabrafenib + trametinib in melanoma (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Started Dec 2010; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-015298-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015298-11.